Navigation Links
Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
Date:9/25/2007

leukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals, including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market
'/>"/>

SOURCE Interleukin Genetics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
4. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
5. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
6. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
7. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
8. Researchers Identify New Genetic Risk Factors for Type 2 Diabetes
9. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
10. Myriad Genetics Presents Tumor Origin Technology at AACR
11. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... SAN DIEGO, Feb. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE ... patient enrollment in its bioequivalence study of ANX-514 (docetaxel ... announce results from this study in the second quarter ... chemotherapeutic agent, Taxotere(R), an anti-cancer agent that is approved ...
... to monitor health outcomes in Fresno, California LOS ALTOS, ... Foundation (GHRF) today announced that it has received a ... treatment in California,s Central Valley, a region with the ... grant will help fund data collection and analysis at ...
Cached Medicine Technology:ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 2ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 3Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in California's Central Valley 2
(Date:7/13/2014)... in The Lancet Neurology calls for ... term neurological problems that repeated concussions can cause. ... of sports-related traumatic brain injury (TBI), and the ... amyotrophic lateral sclerosis, and other neurological disorders, say ... concerning, is that even when the symptoms of ...
(Date:7/13/2014)... 13, 2014 Carolinas Healthcare System celebrated ... the Carolinas HealthCare System - Anson located in Anson ... Anson Community Hospital in Wadesboro. , Located on U.S. ... from the previous facility. Situated on a 10-acre site, ... an emergency room drop-off, helipad, healing garden, and 15 ...
(Date:7/13/2014)... portable, microchip-based test for diagnosing type-1 diabetes could ... understand the disease, according to the device,s inventors ... Described in a paper to be published online ... test employs nanotechnology to detect type-1 diabetes outside ... two main forms of diabetes mellitus, which are ...
(Date:7/13/2014)... Victorian Hotel has recently announced that it ... bikes for its "Cycle the City" program, which encourages ... the area using a rental bicycle, available for just ... call Vancouver home, as it is a city with ... journeys through the countryside. Vancouver hotel rooms often play ...
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
Breaking Medicine News(10 mins):Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4
... high health-care costs it has become a burden both on ... as a respite comes a new cardio drug that negates ... ,The drug is in the African-American heart failure patients where ... Angus, M.D., M.P.H., professor of critical care medicine at the ...
... A liver transplant operation has been conducted on a six-year-old ... underwent the surgery celebrates his birthday on 19 December 2005. ... 'The kid is still in ICU but is responding well ... hope his condition will be normal soon.' , ,He ...
... Clinic say that the flagship breast cancer drug, tamoxifen might ... genetic variation. // ,This particular variant gene has the ... is vital to activate tamoxifen against breast cancer. The study ... of Michigan Comprehensive Cancer Center and Matthew Goetz, M.D., an ...
... is responsible for the death of Rene Anderson, a diabetic ... was prescribed to Mrs. Anderson to ease the numbness and ... // ,The medicine is reported to have resulted disturbed ... an intoxicated and confused state. Here her condition continued to ...
... formed a new cabinet committee to plan strategies to fight ... said that though the United Kingdom //Government has taken various ... spread but the committee feels still a lot has to ... committee feels that the Government should organize the food sector ...
... easily subsided by administering sweet to children now has a ... ,They have reported that the analgesic efficacy of sweet ... sweet taste and by the child's weight status. This appears ... just because they taste good, but also because sweets make ...
Cached Medicine News:Health News:A cost effective heart failure drug hits the market! 2Health News:Sweet pain releiver! 2
... Workstations provide comprehensive neurological monitoring in ... unit to accurately access your patients ... 15 years experience, and a long ... neurological monitoring systems have a proven ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
The Nicolet Bravo™ is a Multi-application system that can configure to meet the needs of neurophysiology department....
... system especially designed for surgical monitoring and ... channels and is equipped with two headboxes ... can be independently configured as either a ... Endeavor amplifiers are based on the Firewire ...
Medicine Products: